Join Minerva Neurosciences for an in-person and virtual event featuring several key opinion leaders and company management to discuss the unmet need and current landscape related to the treatment of negative symptoms of schizophrenia. Management will also discuss new analytical evidence supporting roluperidone’s efficacy as well as other important company updates.

Roluperidone, an investigational therapy for negative symptoms of schizophrenia, is the only monotherapy treatment to date, to demonstrate significant meaningful improvements on primary negative symptoms of schizophrenia. Currently, no FDA-approved therapies exist for negative symptoms, and roluperidone remains the only late-stage drug in development targeting primary negative symptoms.

During the event, company management will also review the market opportunity for roluperidone. A live question and answer session will follow the formal presentations.